AnHorn Medicines Gains FDA IND Clearance and Taiwan CDE Index Case for AH-008
AnHorn Medicines announced that its neuroprotective candidate AH-008 has received U.S. FDA IND clearance and Taiwan CDE Index Case designation, enabling the company to begin clinical trials for preventing chemotherapy-induced peripheral neuropathy.